

DT05 Rec'd PCT/PTO 14 DEC 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Doan et al.

Serial No.: PCT/US2003/020094

Group Art Unit:

File Date: June 25, 2003

Examiner:

For: **Preparation of Stereoisomers of (3Alpha, 3Alpha/Beta, 6Alpha/Beta)Hexahydrofuro[2,3-b]Furan-3-OL**

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: *ref. #4*
☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))
☒ A copy of the International Search Report which issued on International Application No. PCT/US2003/020094 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
☐ **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311, whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

10/517966


DT05 PCT/PTO 14 DEC 2004

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Karen L. Prus
Registration No. 39,337

Date: *December 14, 2004*
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-2192
Facsimile: (919) 483-7988

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENTATTORNEY DOCKET NO.
PU4754USWSERIAL NO.
107517966
Not Being Assigned

APPLICANT: Doan et al.

FILING DATE:
Concurrently Herewith

GROUP

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page _____

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	1	WO 03/024974	Mar. 27, 2003	WIPO		
	2	WO 03/022853	Mar. 20, 2003	WIPO		
	3	WO 02/060905	Aug. 8, 2002	WIPO		
	4	WO 94/26749	No. 24, 1994	WIPO		

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

5	Mayer, S., et al. "Synthesis of Perhydro-Furo'2,3-b!Pyran (and Furan)-3-yl Methanols by Oxygenative Radical Cyclization." Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, Vol. 54, No. 30, July 23, 1998, pgs 8753-8770.
6	Ghosh, A.K., et al. "Nonpeptidal P2 Ligands for HIV Protease Inhibitors: Structure-Based Design, Synthesis, and Biological Evaluation." Journal of Medicinal Chemistry, American Chemical Society, Washington, US, Vol. 39, No. 17, 1996, pgs. 3278-3290.
7	Uchiyama, M., et al. "Stereoselective Synthesis of Optically Active Perhydrofuro'2,3-b!furan Derivatives." Tetrahedron Letters, Elsevier Science Publishers, Amerstam, NL, Vol. 42, No. 28, July 9, 2001, pgs 4653-4656.
8	Ghosh, A.K., et al. "Synthesis and Optical Resolution of High Affinity P2-Ligands for HIV-1 Protease Inhibitors." Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL, Vol. 36, No. 4, Jan. 23, 1995, pgs. 505-508.

Continue on page _____

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.